Prohibition Partners
Home / Reports & Data / The Global Cannabis Report: 3rd Edition
ReportGlobal

The Global Cannabis Report: 3rd Edition

Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026.

  • Analyst-written market analysis
  • PDF + data
  • Published 2021

Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.

Trusted by teams at

DIAGEOKPMGBarclaysNovartisBloomberg

About this edition

Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.

PDF + data

delivery format

2021

published

Inside this edition

Overview

Prohibition Partners estimates that, in 2022, the global sales of CBD, medical and adult-use cannabis amounted to US$45 billion and could be worth more than US$101 billion by 2026. Cannabis liberalisation is accelerating, with an increasing number of States and countries legalising cannabis for adult-use and medical purposes The financial climate for cannabis operators remains tough, as impacts from the COVID pandemic and Russia-Ukraine war slow the flow of capital to the industry

Contents10
  • Legislation
  • Supply chain
  • Social issues
  • Finance
  • Continents
  • Expert Interviews
  • Oren Lebovitch, The Israeli Cannabis Magazine
  • Patrick McCartan, Regennabis
  • Crystal Millican, Cookies
  • Conclusions
Key findings8
  • Legalisation of high THC cannabis for non-medical purposes will soon be a reality in several countries around the world, with some nations like Germany and Colombia recently announcing their intention to legalise.
  • The legalisation of medical cannabis did not progress as quickly in 2022 as in previous years, with just a few countries declaring their intention to legalise for medical purposes.
  • In Latin America, both Costa Rica and Panama adopted their medical cannabis laws for the first time in 2022.
  • In Europe, the Spanish government legalised the magistral use of medical cannabis for select conditions through the country's public health system in June 2022. In the same month, the Ukrainian Minister of Health, Viktor Liashko, expressed his intent to legalise cannabis for medical purposes as part of the country's efforts to treat trauma as a result of the war.
  • In Asia, in August 2022, a spokesperson for the Malaysian Ministry of Health stated the country's intention to legalise medical cannabis, taking inspiration from the system previously set up in Thailand.
  • In October 2022, the US President, Joe Biden, announced an amnesty for people imprisoned for simple cannabis possession. This act will benefit thousands of individual prisoners, but its main purpose is that it is a symbolic act for the benefit of American states and the international community showing that the US now favours at least the decriminalisation of adult-use cannabis.
  • As of late 2022, only Uruguay, Canada and a handful of states in the US have fully legalised the commercial sale of cannabis for adult-use, with more states soon to vote on adult-use legalisation measures.
  • There is a strong feeling among many advocates and industry stakeholders that we are currently at the beginning of a zeitgeist when it comes to the commercial legalisation of adult-use cannabis globally.

Who it’s for

Investors & analysts

Defensible sizing and forecasts to underwrite the thesis.

Corporate strategy & FMCG

Opportunity sizing and entry routes across key markets.

More from the library

All research